Table 4 Open in new tab Univariate...

Characteristics	OR (95% CI)	P	OR (95% CI)	P
Age	1.04 (1.01–1.07)	0.002	1.06 (1.01–1.08)	0.008
Male	1.62 (1.02–2.56)	0.022	1.67 (1.02–2.74)	0.041
CKD	0.82 (0.49–1.35)	0.438	0.91 (0.52–1.58)	0.750
PM/ICD	1.39 (0.85–2.29)	0.193	1.26 (0.72–2.21)	0.410
Diuretic therapy increase at 2-month			0.98 (0.52–1.86)	0.963
Diuretic therapy reduction at 2-month			1.16 (0.68–1.97)	0.580
Beta-blocker therapy	1.59 (0.88–2.90)	0.127	2.68 (1.19–6.01)	0.017
Anti-RAAS therapy	1.21 (0.77–1.90)	0.402	1.15 (0.69–1.91)	0.586
MRA therapy	1.17 (0.75–1.82)	0.482	1.06 (0.65–1.73)	0.809
T-TEER	2.15 (1.14–4.05)	0.018	1.88 (0.91–3.88)	0.087
Annuloplasty	0.75 (0.34–1.66)	0.474	0.80 (0.29–2.17)	0.670
Orthotopic replacement	0.18 (0.03–1.40)	0.101	0.37 (0.04–3.26)	0.374
Heterotopic replacement	0.67 (0.18–2.53)	0.557	0.63 (0.12–3.17)	0.574
Procedural success	3.3 (1.58–7.02)	0.002	2.98 (1.27–6.99)	0.012
TR reduction to at least moderate degree	2.26 (1.29–3.92)	0.004	2.29 (1.22–4.33)	0.010
Baseline LVEDD	1.06 (1.03–1.09)	<0.001	1.02 (0.99–4.77)	0.125
LVEDD > 60 mm	2.27 (1.02–5.07)	0.045	2.09 (0.92–4.77)	0.077
Pre-discharge LVEDD	1.05 (1.02–1.08)	0.002	1.04 (1.01–1.06)	0.027
Delta LVEDD	0.98 (0.95–1.02)	0.399	1.02 (0.98–1.06)	0.302
Baseline LVEF	0.96 (0.94–0.98)	<0.001	0.96 (0.94–0.98)	0.002
Baseline LVEF < 30%	3.01 (1.36–6.89)	0.007	2.2 (0.88–5.73)	0.090
Delta LVEF	0.99 (0.95–1.02)	0.518	1.00 (0.97–1.05)	0.822
Pre-discharge LVEF	0.96 (0.94–0.98)	<0.001	0.97 (0.95–0.99)	0.005
Baseline TAPSE	0.96 (0.91–1.01)	0.129	0.95 (0.89–1.01)	0.078
Baseline TAPSE < 17 mm	1.54 (0.76–3.11)	0.228	2.20 (0.89–5.37)	0.086
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.66–3.21)	0.356	1.10 (0.65–1.87)	0.710
Pre-discharge TAPSE	1.04 (0.97–1.09)	0.244	1.03 (0.96–1.10)	0.336
Atrial fibrillation	0.46 (0.29–0.73)	0.001	0.78 (0.47–1.27)	0.319

Characteristics

OR (95% CI)

Pre-discharge (n = 106)

2-month follow-up (n = 99)

Age

1.04 (1.01–1.07)

0.002

1.06 (1.01–1.08)

0.008

Male

1.62 (1.02–2.56)

0.022

1.67 (1.02–2.74)

0.041

CKD

0.82 (0.49–1.35)

0.438

0.91 (0.52–1.58)

0.750

PM/ICD

1.39 (0.85–2.29)

0.193

1.26 (0.72–2.21)

0.410

Diuretic therapy increase at 2-month

0.98 (0.52–1.86)

0.963

Diuretic therapy reduction at 2-month

1.16 (0.68–1.97)

0.580

Beta-blocker therapy

1.59 (0.88–2.90)

0.127

2.68 (1.19–6.01)

0.017

Anti-RAAS therapy

1.21 (0.77–1.90)

0.402

1.15 (0.69–1.91)

0.586

MRA therapy

1.17 (0.75–1.82)

0.482

1.06 (0.65–1.73)

0.809

T-TEER

2.15 (1.14–4.05)

0.018

1.88 (0.91–3.88)

0.087

Annuloplasty

0.75 (0.34–1.66)

0.474

0.80 (0.29–2.17)

0.670

Orthotopic replacement

0.18 (0.03–1.40)

0.101

0.37 (0.04–3.26)

0.374

Heterotopic replacement

0.67 (0.18–2.53)

0.557

0.63 (0.12–3.17)

0.574

Procedural success

3.3 (1.58–7.02)

0.002

2.98 (1.27–6.99)

0.012

TR reduction to at least moderate degree

2.26 (1.29–3.92)

0.004

2.29 (1.22–4.33)

0.010

Baseline LVEDD

1.06 (1.03–1.09)

<0.001

1.02 (0.99–4.77)

0.125

LVEDD > 60 mm

2.27 (1.02–5.07)

0.045

2.09 (0.92–4.77)

0.077

Pre-discharge LVEDD

1.05 (1.02–1.08)

0.002

1.04 (1.01–1.06)

0.027

Delta LVEDD

0.98 (0.95–1.02)

0.399

1.02 (0.98–1.06)

0.302

Baseline LVEF

0.96 (0.94–0.98)

<0.001

0.96 (0.94–0.98)

0.002

Baseline LVEF < 30%

3.01 (1.36–6.89)

0.007

2.2 (0.88–5.73)

0.090

Delta LVEF

0.99 (0.95–1.02)

0.518

1.00 (0.97–1.05)

0.822

Pre-discharge LVEF

0.96 (0.94–0.98)

<0.001

0.97 (0.95–0.99)

0.005

Baseline TAPSE

0.96 (0.91–1.01)

0.129

0.95 (0.89–1.01)

0.078

Baseline TAPSE < 17 mm

1.54 (0.76–3.11)

0.228

2.20 (0.89–5.37)

0.086

Baseline RV impairment (TAPSE/sPAP < 0.406)

1.45 (0.66–3.21)

0.356

1.10 (0.65–1.87)

0.710

Pre-discharge TAPSE

1.04 (0.97–1.09)

0.244

1.03 (0.96–1.10)

0.336

Atrial fibrillation

0.46 (0.29–0.73)

0.001

0.78 (0.47–1.27)

0.319

Characteristics	OR (95% CI)	P	OR (95% CI)	P
Age	1.04 (1.01–1.07)	0.002	1.06 (1.01–1.08)	0.008
Male	1.62 (1.02–2.56)	0.022	1.67 (1.02–2.74)	0.041
CKD	0.82 (0.49–1.35)	0.438	0.91 (0.52–1.58)	0.750
PM/ICD	1.39 (0.85–2.29)	0.193	1.26 (0.72–2.21)	0.410
Diuretic therapy increase at 2-month			0.98 (0.52–1.86)	0.963
Diuretic therapy reduction at 2-month			1.16 (0.68–1.97)	0.580
Beta-blocker therapy	1.59 (0.88–2.90)	0.127	2.68 (1.19–6.01)	0.017
Anti-RAAS therapy	1.21 (0.77–1.90)	0.402	1.15 (0.69–1.91)	0.586
MRA therapy	1.17 (0.75–1.82)	0.482	1.06 (0.65–1.73)	0.809
T-TEER	2.15 (1.14–4.05)	0.018	1.88 (0.91–3.88)	0.087
Annuloplasty	0.75 (0.34–1.66)	0.474	0.80 (0.29–2.17)	0.670
Orthotopic replacement	0.18 (0.03–1.40)	0.101	0.37 (0.04–3.26)	0.374
Heterotopic replacement	0.67 (0.18–2.53)	0.557	0.63 (0.12–3.17)	0.574
Procedural success	3.3 (1.58–7.02)	0.002	2.98 (1.27–6.99)	0.012
TR reduction to at least moderate degree	2.26 (1.29–3.92)	0.004	2.29 (1.22–4.33)	0.010
Baseline LVEDD	1.06 (1.03–1.09)	<0.001	1.02 (0.99–4.77)	0.125
LVEDD > 60 mm	2.27 (1.02–5.07)	0.045	2.09 (0.92–4.77)	0.077
Pre-discharge LVEDD	1.05 (1.02–1.08)	0.002	1.04 (1.01–1.06)	0.027
Delta LVEDD	0.98 (0.95–1.02)	0.399	1.02 (0.98–1.06)	0.302
Baseline LVEF	0.96 (0.94–0.98)	<0.001	0.96 (0.94–0.98)	0.002
Baseline LVEF < 30%	3.01 (1.36–6.89)	0.007	2.2 (0.88–5.73)	0.090
Delta LVEF	0.99 (0.95–1.02)	0.518	1.00 (0.97–1.05)	0.822
Pre-discharge LVEF	0.96 (0.94–0.98)	<0.001	0.97 (0.95–0.99)	0.005
Baseline TAPSE	0.96 (0.91–1.01)	0.129	0.95 (0.89–1.01)	0.078
Baseline TAPSE < 17 mm	1.54 (0.76–3.11)	0.228	2.20 (0.89–5.37)	0.086
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.66–3.21)	0.356	1.10 (0.65–1.87)	0.710
Pre-discharge TAPSE	1.04 (0.97–1.09)	0.244	1.03 (0.96–1.10)	0.336
Atrial fibrillation	0.46 (0.29–0.73)	0.001	0.78 (0.47–1.27)	0.319

Table 4

Open in new tab

Univariate analyses for the outcome MR improvement at both pre-discharge and 2-month echocardiographic assessment

Characteristics	OR (95% CI)	P	OR (95% CI)	P
	Pre-discharge (n = 106)		2-month follow-up (n = 99)
Age	1.04 (1.01–1.07)	0.002	1.06 (1.01–1.08)	0.008
Male	1.62 (1.02–2.56)	0.022	1.67 (1.02–2.74)	0.041
CKD	0.82 (0.49–1.35)	0.438	0.91 (0.52–1.58)	0.750
PM/ICD	1.39 (0.85–2.29)	0.193	1.26 (0.72–2.21)	0.410
Diuretic therapy increase at 2-month			0.98 (0.52–1.86)	0.963
Diuretic therapy reduction at 2-month			1.16 (0.68–1.97)	0.580
Beta-blocker therapy	1.59 (0.88–2.90)	0.127	2.68 (1.19–6.01)	0.017
Anti-RAAS therapy	1.21 (0.77–1.90)	0.402	1.15 (0.69–1.91)	0.586
MRA therapy	1.17 (0.75–1.82)	0.482	1.06 (0.65–1.73)	0.809
T-TEER	2.15 (1.14–4.05)	0.018	1.88 (0.91–3.88)	0.087
Annuloplasty	0.75 (0.34–1.66)	0.474	0.80 (0.29–2.17)	0.670
Orthotopic replacement	0.18 (0.03–1.40)	0.101	0.37 (0.04–3.26)	0.374
Heterotopic replacement	0.67 (0.18–2.53)	0.557	0.63 (0.12–3.17)	0.574
Procedural success	3.3 (1.58–7.02)	0.002	2.98 (1.27–6.99)	0.012
TR reduction to at least moderate degree	2.26 (1.29–3.92)	0.004	2.29 (1.22–4.33)	0.010
Baseline LVEDD	1.06 (1.03–1.09)	<0.001	1.02 (0.99–4.77)	0.125
LVEDD > 60 mm	2.27 (1.02–5.07)	0.045	2.09 (0.92–4.77)	0.077
Pre-discharge LVEDD	1.05 (1.02–1.08)	0.002	1.04 (1.01–1.06)	0.027
Delta LVEDD	0.98 (0.95–1.02)	0.399	1.02 (0.98–1.06)	0.302
Baseline LVEF	0.96 (0.94–0.98)	<0.001	0.96 (0.94–0.98)	0.002
Baseline LVEF < 30%	3.01 (1.36–6.89)	0.007	2.2 (0.88–5.73)	0.090
Delta LVEF	0.99 (0.95–1.02)	0.518	1.00 (0.97–1.05)	0.822
Pre-discharge LVEF	0.96 (0.94–0.98)	<0.001	0.97 (0.95–0.99)	0.005
Baseline TAPSE	0.96 (0.91–1.01)	0.129	0.95 (0.89–1.01)	0.078
Baseline TAPSE < 17 mm	1.54 (0.76–3.11)	0.228	2.20 (0.89–5.37)	0.086
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.66–3.21)	0.356	1.10 (0.65–1.87)	0.710
Pre-discharge TAPSE	1.04 (0.97–1.09)	0.244	1.03 (0.96–1.10)	0.336
Atrial fibrillation	0.46 (0.29–0.73)	0.001	0.78 (0.47–1.27)	0.319

Characteristics	OR (95% CI)	P	OR (95% CI)	P
	Pre-discharge (n = 106)		2-month follow-up (n = 99)
Age	1.04 (1.01–1.07)	0.002	1.06 (1.01–1.08)	0.008
Male	1.62 (1.02–2.56)	0.022	1.67 (1.02–2.74)	0.041
CKD	0.82 (0.49–1.35)	0.438	0.91 (0.52–1.58)	0.750
PM/ICD	1.39 (0.85–2.29)	0.193	1.26 (0.72–2.21)	0.410
Diuretic therapy increase at 2-month			0.98 (0.52–1.86)	0.963
Diuretic therapy reduction at 2-month			1.16 (0.68–1.97)	0.580
Beta-blocker therapy	1.59 (0.88–2.90)	0.127	2.68 (1.19–6.01)	0.017
Anti-RAAS therapy	1.21 (0.77–1.90)	0.402	1.15 (0.69–1.91)	0.586
MRA therapy	1.17 (0.75–1.82)	0.482	1.06 (0.65–1.73)	0.809
T-TEER	2.15 (1.14–4.05)	0.018	1.88 (0.91–3.88)	0.087
Annuloplasty	0.75 (0.34–1.66)	0.474	0.80 (0.29–2.17)	0.670
Orthotopic replacement	0.18 (0.03–1.40)	0.101	0.37 (0.04–3.26)	0.374
Heterotopic replacement	0.67 (0.18–2.53)	0.557	0.63 (0.12–3.17)	0.574
Procedural success	3.3 (1.58–7.02)	0.002	2.98 (1.27–6.99)	0.012
TR reduction to at least moderate degree	2.26 (1.29–3.92)	0.004	2.29 (1.22–4.33)	0.010
Baseline LVEDD	1.06 (1.03–1.09)	<0.001	1.02 (0.99–4.77)	0.125
LVEDD > 60 mm	2.27 (1.02–5.07)	0.045	2.09 (0.92–4.77)	0.077
Pre-discharge LVEDD	1.05 (1.02–1.08)	0.002	1.04 (1.01–1.06)	0.027
Delta LVEDD	0.98 (0.95–1.02)	0.399	1.02 (0.98–1.06)	0.302
Baseline LVEF	0.96 (0.94–0.98)	<0.001	0.96 (0.94–0.98)	0.002
Baseline LVEF < 30%	3.01 (1.36–6.89)	0.007	2.2 (0.88–5.73)	0.090
Delta LVEF	0.99 (0.95–1.02)	0.518	1.00 (0.97–1.05)	0.822
Pre-discharge LVEF	0.96 (0.94–0.98)	<0.001	0.97 (0.95–0.99)	0.005
Baseline TAPSE	0.96 (0.91–1.01)	0.129	0.95 (0.89–1.01)	0.078
Baseline TAPSE < 17 mm	1.54 (0.76–3.11)	0.228	2.20 (0.89–5.37)	0.086
Baseline RV impairment (TAPSE/sPAP < 0.406)	1.45 (0.66–3.21)	0.356	1.10 (0.65–1.87)	0.710
Pre-discharge TAPSE	1.04 (0.97–1.09)	0.244	1.03 (0.96–1.10)	0.336
Atrial fibrillation	0.46 (0.29–0.73)	0.001	0.78 (0.47–1.27)	0.319

Bold values denote statistical significance at the p < 0.05 level.

Abbreviations: ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; PM, pacemaker; RAAS, renin–angiotensin–aldosteron; RV, right ventricle; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annulus plane systolic excursion; T-TEER, tricuspid transcatheter edge-to-edge repair.

This Feature Is Available To Subscribers Only